- Adjuvant therapy with ipilimumab is associated with improved recurrence, metastasis, and survival outcomes of patients with stage III melanoma in long-term follow-up of the European Organisation for Research and Treatment of Cancer (EORTC) 18071 trial.
Why this matters
- This follow-up study provides evidence for sustained benefit of ipilimumab for patients with resected, stage III melanoma.
- 7-year recurrence-free survival (RFS) was 39.2% in patients who received ipilimumab and 30.9% in patients who received placebo.
- 7-year distant metastases-free survival (DMFS) was 44.5% in patients who received ipilimumab and 36.9% in patients who received placebo.
- 7-year OS was 60.0% in patients who received ipilimumab and 51.3% in patients who received placebo.
- Compared with placebo, ipilimumab was associated with longer:
- RFS (HR, 0.75; P<.001>
- DMFS (HR, 0.76; P=.002), and
- OS (HR, 0.73; P=.002).
- 951 patients with resected stage III cutaneous melanoma from 99 sites were randomly assigned to receive ipilimumab or placebo for up to 3 years.
- 264 patients had recent follow-up data (6.9 years median follow-up).
- Funding: Bristol-Myers Squibb.
- Many patients lost to follow-up.